Evidence map›Paper›PMID 38494079›Full record

ArticleThe Journal of molecular diagnostics : JMD2024

DNA Reference Reagents for Genotyping RH Variants.

Emilia Sippert, Evgeniya Volkova, Meagan Rippee-Brooks, Gregory A Denomme, Willy A Flegel, Christine Lee, Richardae Araojo, Orieji Illoh, Zhugong Liu, Maria Rios and 1 more

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of molecular diagnostics : JMD, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. Article
  2. Resolution ofInternational journal of molecular sciences · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Emilia SippertOffice of Blood Research and Review, Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland. Electronic address: emilia.sippert@fda.hhs.gov.
Evgeniya VolkovaOffice of Blood Research and Review, Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland.
Meagan Rippee-BrooksOffice of Blood Research and Review, Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland.
Gregory A DenommeVersiti Blood Research Institute, Versiti Blood Center of Wisconsin, Milwaukee, Wisconsin; Diagnostic Laboratories, Versiti Blood Center of Wisconsin, Milwaukee, Wisconsin.
Willy A FlegelDepartment of Transfusion Medicine, NIH Clinical Center, National Institutes of Health, Bethesda, Maryland.
Christine LeeOffice of Minority Health and Health Equity, Office of the Commissioner, US Food and Drug Administration, Silver Spring, Maryland.
Richardae AraojoOffice of Minority Health and Health Equity, Office of the Commissioner, US Food and Drug Administration, Silver Spring, Maryland.
Orieji IllohOffice of Blood Research and Review, Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland.
Zhugong LiuOffice of Blood Research and Review, Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland.
Maria RiosOffice of Blood Research and Review, Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland. Electronic address: maria.rios@fda.hhs.gov.
Collaborative Study Group
Center for Biologics Evaluation and Research · USNational Institutes of Health Clinical Center · USUnited States Food and Drug Administration · USVersiti Blood Center of Wisconsin · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Patients who carry Rhesus (RH) blood group variants may develop Rh alloantibodies requiring matched red blood cell transfusions. Serologic reagents for Rh variants often fail to specifically identify variant Rh antigens and are in limited supply. Therefore, red blood cell genotyping assays are essential for managing transfusions in patients with clinically relevant Rh variants. Well-characterized DNA reference reagents are needed to ensure quality and accuracy of the molecular tests. Eight lyophilized DNA reference reagents, representing 21 polymorphisms in RHD and RHCE, were produced from an existing repository of immortalized B-lymphoblastoid cell lines at the Center for Biologics Evaluation and Research/US Food and Drug Administration. The material was validated through an international collaborative study involving 17 laboratories that evaluated each DNA candidate using molecular assays to characterize RHD and RHCE alleles, including commercial platforms and laboratory-developed testing, such as Sanger sequencing, next-generation sequencing, and third-generation sequencing. The genotyping results showed 99.4% agreement with the expected results for the target RH polymorphisms and 87.9% for RH allele agreement. Most of the discordant RH alleles results were explained by a limited polymorphism coverage in some genotyping methods. Results of stability and accelerated degradation studies support the suitability of these reagents for use as reference standards. The collaborative study results demonstrate the qualification of these eight DNA reagents for use as reference standards for RH blood group genotyping assay development and analytical validation.

Indexed as

Genotyping TechniquesRh-Hr Blood-Group SystemAllelesDNAGenotypeHigh-Throughput Nucleotide SequencingHumansIndicators and ReagentsPolymorphism, GeneticReference StandardsDNAIndicators and ReagentsRHCE protein, humanRh-Hr Blood-Group SystemRho(D) antigen

Identifiers

PMID38494079
PMCPMC11238275
OpenAlexW4392888602

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.